Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with90Y ibritumomab tiuxetan in a phase II study-Reference-Cited by-同舟云学术

Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with90Y ibritumomab tiuxetan in a phase II study

Published:2018-04-30 Issue:3 Volume:36 Page:525-532
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Berinstein Neil L.¹²,Pennell Nancy M.³^ORCID,Weerasinghe Rashmi¹,Buckstein Rena¹²,Piliotis Eugenia¹²,Imrie Kevin R.¹²,Chodirker Lisa¹²,Cussen Mary-Anne¹,Miles Ellen¹,Reis Marciano D.³²,Ghorab Zeina³²,Cheung Matthew C.¹²

Affiliation:

1. Odette Cancer Centre; Sunnybrook Health Sciences Centre; Toronto ON Canada

2. Department of Medicine; University of Toronto; Toronto ON Canada

3. Department of Laboratory Medicine; Sunnybrook Health Sciences Centre; Toronto ON Canada

Funder

Spectrum Pharmaceuticals

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hon.2513/fullpdf

Reference23 articles.

1. Follicular lymphoma international prognostic index;Solal-Celigny;Blood,2004

2. Validation, revision and extension of the follicular lymphoma international prognostic index (FLIPI) in a population-based setting;Schans;Ann Oncol,2009

3. Zevalin((R)) (ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned?;Rizzieri;Crit Rev Oncol Hematol,2016

4. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-LineIndolent trial;Morschhauser;J Clin Oncol,2013

5. Minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma;Hiddemann;Ann Oncol,2005

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

2. Adverse events of radioimmunotherapy for non-Hodgkin lymphoma: A systematic review and meta-analysis;Leukemia Research;2021-09

3. Consolidation with 90 Yttrium‐ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma;Hematological Oncology;2020-10-07

4. Evolving role of biomaterials in diagnostic and therapeutic radiation oncology;Bioactive Materials;2020-06